A 48-hour-old preterm neonate (34 weeks gestation) with ABO incompatibility (mother O, baby B) presents with a serum bilirubin of 16 mg/dL and rising rapidly. Phototherapy is being initiated. Which medication should be administered concurrently to reduce hemolysis and prevent further bilirubin rise?

Question

Accepted Answer

C. Intravenous immunoglobulin (IVIG). ## IVIG in Hemolytic Neonatal Jaundice

### Indications for IVIG

**Key Point:** IVIG is the first-line adjunctive therapy in hemolytic disease (Rh or ABO incompatibility) to reduce hemolysis and prevent the need for exchange transfusion.

**High-Yield:** IVIG mechanism:
- Blocks Fc receptors on fetal RBCs, preventing maternal IgG antibody-mediated hemolysis
- Reduces the rate of bilirubin rise by 1–2 mg/dL per day
- Decreases the need for exchange transfusion by ~50% when used with phototherapy

### Dosing and Administration

- **Dose:** 0.5–1 g/kg IV over 2–4 hours
- **Timing:** Administer as soon as hemolytic disease is confirmed, alongside phototherapy
- **Efficacy:** Most effective when given early (within first 24–48 hours of life)

### Clinical Scenario Analysis

In this preterm infant with ABO incompatibility:
- Phototherapy alone may be insufficient due to rapid bilirubin rise
- IVIG reduces hemolysis and buys time to prevent exchange transfusion
- Preterm infants have lower phototherapy thresholds, making IVIG particularly valuable

### Comparison: IVIG vs. Other Interventions in Hemolytic Disease

| Intervention | Mechanism | Onset | Indication |
|---|---|---|---|
| IVIG | Blocks Fc receptors, reduces hemolysis | 6–12 hours | ABO/Rh incompatibility, rising bilirubin |
| Phototherapy | Converts bilirubin to water-soluble isomers | Immediate | All hyperbilirubinemia |
| Exchange transfusion | Removes bilirubin + antibodies | Immediate | Severe/refractory hyperbilirubinemia |
| Phenobarbital | Induces conjugation | 24–48 hours | Rarely used; delayed onset |

**Clinical Pearl:** IVIG is particularly effective in ABO incompatibility (where hemolysis is typically mild-to-moderate) compared to Rh incompatibility. Early administration in preterm infants can prevent escalation to exchange transfusion.

### Why Other Options Are Incorrect

- **Phenobarbital:** Slow onset (24–48 hours); not suitable for acute hemolytic disease
- **Ursodeoxycholic acid:** No role in hemolytic disease or acute hyperbilirubinemia
- **Folic acid:** Not indicated; no effect on hemolysis or bilirubin metabolism

Answer

A. Ursodeoxycholic acid

Answer

B. Folic acid

Answer

D. Phenobarbital

A 48-hour-old preterm neonate (34 weeks gestation) with ABO incompatibility (mother O, baby B) presents with a serum bilirubin of 16 mg/dL and rising rapidly. Phototherapy is being initiated. Which medication should be administered concurrently to reduce hemolysis and prevent further bilirubin rise?

Explanation

IVIG in Hemolytic Neonatal Jaundice

Indications for IVIG

Dosing and Administration

Clinical Scenario Analysis

Comparison: IVIG vs. Other Interventions in Hemolytic Disease

Why Other Options Are Incorrect

Practice similar questions

Join our NEET PG community

Intervention	Mechanism	Onset	Indication
IVIG	Blocks Fc receptors, reduces hemolysis	6–12 hours	ABO/Rh incompatibility, rising bilirubin
Phototherapy	Converts bilirubin to water-soluble isomers	Immediate	All hyperbilirubinemia
Exchange transfusion	Removes bilirubin + antibodies	Immediate	Severe/refractory hyperbilirubinemia
Phenobarbital	Induces conjugation	24–48 hours	Rarely used; delayed onset